Results 21 to 30 of about 5,907 (256)

Alteration of Loperamide-Induced Prostate Relaxation in High-Fat Diet-Fed Rats

The Scientific World Journal, 2014
Objective. To investigate the change of loperamide-induced prostate relaxation in rats fed with high-fat diet (HFD). Materials and Methods. Adult male Wistar rats were divided into 2 groups: (1) control rats fed with normal chow and (2) rats fed with ...
Sheng-Lung Hsu, Hsien-Hui Chung, I-Hung Chen, Yat-Ching Tong   +3 more
doaj   +1 more source

Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations [PDF]

Diabetes Care, 2008
OBJECTIVE—Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations.
Rafiq, Meena, Flanagan, Sarah E., Patch, Ann Marie, Shields, Beverley M., Ellard, Sian, Hattersley, Andrew T., Batra, Chandar, Bruining, Jan, Carson, Dennis, Codner, Ethel, Cummings, Elizabeth, Curran, Jacqueline, Davis, Elizabeth, Deiss, Dorothee, Herr, Mathias, Hussain, Khalid, Legault, Laurent, Malecki, Maciek, Paskova, Magdalena, Pearson, Ewan, Rodda, Christine, Rothenbuhler, Anya, Sanchez, Juan, Shield, Julian, Stanca, Ràcealà Motoc, Van Der Meulen, John   +25 more
openaire   +5 more sources

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease

Cardiovascular Diabetology, 2009
Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors.
Fisman Enrique Z, Tenenbaum Alexander
doaj   +1 more source

Characterization of the rat mesangial cell type 2 sulfonylurea receptor

, 1999
Characterization of the rat mesangial cell type 2 sulfonylurea receptor.BackgroundSulfonylurea receptors are classified as either high-affinity type 1 (SUR1) or low-affinity type 2 receptors (SUR2), and the gene expression of SURs has recently been ...
Garvin, Jeffrey L, Garvin, Jeffrey L., Rodríguez-Barbero, Alicia, Riser, Bruce L, Cortes, Pedro, Riser, Bruce L., Szamosfalvi, Balázs, Asano, Kenichiro, Yee, Jerry   +8 more
core   +1 more source

NEW IN THE TREATMENT OF TYPE 2 DIABETES

Zaporožskij Medicinskij Žurnal, 2014
Diabetes mellitus (DM) is a major medical and social problem almost in all countries of the world. Currently, there are more and more various pharmacological agents that make management of the glycaemia in patients with type 2 diabetes extremely ...
V. G. Kadzharyan, N. I. Kapshytar
doaj   +1 more source

Sulfonylurea Receptor 1 Expression in Human Cerebral Infarcts [PDF]

Journal of Neuropathology & Experimental Neurology, 2013
In animal models of stroke, sulfonylurea receptor 1 (Sur1), a member of the adenosine triphosphate binding cassette transporter gene family, is transcriptionally upregulated in neural and vascular cells in which it plays a leading role in edema formation and necrotic cell death. To date, expression of Sur1 in the brains of humans with cerebral infarcts
Mehta, Rupal I., Ivanova, Svetlana, Tosun, Cigdem, Castellani, Rudy J., Gerzanich, Volodymyr, Simard, J. Marc   +5 more
openaire   +2 more sources

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

, 1997
Sulfonylurea derivatives are hypoglycemic drugs frequently used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). In the beta-cell sulfonylureas act by blocking ATP-sensitive potassium channels (K.ATP channels).
Wilde, A. A., Schotborgh, C. E.
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Developmental and Tissue-Specific Sulfonylurea Receptor Gene Expression [PDF]

Endocrinology, 1997
We have studied the developmental regulation of mouse sulfonylurea receptor (SUR) gene expression throughout several embryonic stages as well as in the adult mouse. To this end we used a 229-bp mouse complementary DNA corresponding to the 3'-end of the SUR gene for in situ hybridization and solution hybridization/ribonuclease protection assays.
C, Hernández-Sánchez, T L, Wood, D, LeRoith   +2 more
openaire   +2 more sources